Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verastem Inc VSTM

Healthcare Biotechnology
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced... see more

Recent & Breaking News (NDAQ:VSTM)

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Business Wire September 28, 2023

Verastem Oncology to Participate in Upcoming Investor Conferences

Business Wire September 5, 2023

Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers

Business Wire August 28, 2023

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Business Wire August 8, 2023

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer

Business Wire July 11, 2023

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 10, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire July 5, 2023

Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Business Wire June 16, 2023

Verastem Oncology Announces Reverse Stock Split

Business Wire May 31, 2023

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

Business Wire May 25, 2023

Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors

Business Wire May 16, 2023

Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Business Wire May 9, 2023

Verastem Oncology to Participate in Upcoming Investor Conferences

Business Wire May 1, 2023

New Data from Interim Analysis of Verastem Oncology's RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

Business Wire April 26, 2023

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days

Business Wire April 18, 2023

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 6, 2023

New Verastem Oncology Initiative, Let's Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer

Business Wire March 15, 2023

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Business Wire March 14, 2023

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

Business Wire February 2, 2023

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

Business Wire January 24, 2023